Equities research analysts at Evercore ISI began coverage on shares of Allergan (NYSE:AGN) in a research report issued to clients and investors on Monday. The brokerage set an “outperform” rating on the stock.
Other equities research analysts have also recently issued reports about the company. UBS set a $250.00 price objective on Allergan and gave the stock a “buy” rating in a report on Wednesday, January 10th. Deutsche Bank restated a “buy” rating and set a $215.00 target price on shares of Allergan in a report on Tuesday, January 9th. Citigroup lowered their target price on Allergan to $215.00 and set a “buy” rating on the stock in a report on Tuesday, January 9th. Wells Fargo set a $245.00 target price on Allergan and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, Royal Bank of Canada set a $218.00 target price on Allergan and gave the stock a “buy” rating in a report on Thursday, January 4th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $220.91.
AGN stock traded down $0.08 during trading on Monday, hitting $158.51. The stock had a trading volume of 3,180,410 shares, compared to its average volume of 3,208,273. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38. Allergan has a twelve month low of $142.81 and a twelve month high of $256.80. The stock has a market cap of $55,215.16, a price-to-earnings ratio of 9.69, a PEG ratio of 1.13 and a beta of 1.17.
In related news, insider William Meury sold 58,879 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total value of $9,457,144.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Maria Teresa Hilado acquired 895 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was acquired at an average price of $167.39 per share, for a total transaction of $149,814.05. The disclosure for this purchase can be found here. Insiders purchased 8,095 shares of company stock worth $1,258,081 over the last quarter. 0.37% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avestar Capital LLC acquired a new position in Allergan in the fourth quarter valued at approximately $113,000. Focused Wealth Management Inc raised its position in Allergan by 4,444.4% in the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after purchasing an additional 800 shares during the period. Acropolis Investment Management LLC purchased a new stake in Allergan in the fourth quarter valued at approximately $153,000. Field & Main Bank purchased a new stake in Allergan in the fourth quarter valued at approximately $155,000. Finally, Captrust Financial Advisors purchased a new stake in Allergan in the fourth quarter valued at approximately $175,000. Hedge funds and other institutional investors own 78.35% of the company’s stock.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.